Human health and medicine

Olvimulogene nanivacirepvec

Olvimulogene nanivacirepvec (Olvi-Vec, GL-ONC1, GLV-1h68) is Genelux's investigational oncolytic vaccinia virus (LIVP strain) with reporter-gene insertions, tested in over 150 patients; lead program is phase 3 ovarian cancer (OnPrime/GOG-3076) plus phase 2 NSCLC.

Omadacycline

Omadacycline (NUZYRA, PTK-0796) is a semisynthetic aminomethylcycline tetracycline antibiotic approved in 2018 for adult CABP and ABSSSI, given once daily orally or intravenously, active against tetracycline-resistant bacteria via C-7/C-9 modifications.

Omalizumab

Omalizumab (Xolair), humanized anti-IgE monoclonal antibody approved 2003 for allergic asthma; later indications include nasal polyps, food allergy (first such drug, 2024), and chronic spontaneous urticaria; boxed anaphylaxis warning; biosimilar Omlyclo approved 2025.

Omarigliptin

Omarigliptin (MK-3102, MARIZEV) is Merck's once-weekly oral DPP-4 inhibitor for type 2 diabetes, approved in Japan in 2015; 25 mg weekly showed non-inferior HbA1c reduction to daily sitagliptin.

Omaveloxolone

Omaveloxolone (Skyclarys, RTA 408) is a semisynthetic oleanane triterpenoid Nrf2 activator, the first drug approved for Friedreich's ataxia (FDA 2023, EU 2024), dosed 150 mg once daily.

Ombitasvir

Ombitasvir (ABT-267), also in Viekira Pak, Viekirax, and Technivie, is an AbbVie HCV NS5A inhibitor with picomolar, pan-genotypic potency, used with paritaprevir/ritonavir and dasabuvir; EU marketing authorization withdrawn in 2024.

Ombrabulin

Ombrabulin (AVE8062, AC-7700), a Sanofi water-soluble combretastatin A4 analogue vascular disrupting agent, binds endothelial tubulin to collapse tumor vessels; discontinued after failed sarcoma, NSCLC, and ovarian trials.

Omecamtiv mecarbil

Omecamtiv mecarbil (AMG 423, CK-1827452, Kinharto) is a selective cardiac myosin activator for HFrEF that boosts sarcomere contractility without raising calcium or oxygen use; GALACTIC-HF showed HR 0.92, but EMA rejected approval in 2024.

Omentectomy

Omentectomy is surgery to remove all or part of the greater omentum, the fatty apron of tissue hanging from the stomach, performed mainly during cancer surgery.

Omentopexy

Omentopexy is a surgical technique that mobilizes the greater omentum on its gastroepiploic blood supply and transfers it to cover organs, fill infected spaces, or reinforce repairs.

Omentoplasty

Omentoplasty is a surgical procedure in which the greater omentum is transposed as a vascularized flap to fill defects, control infection, close bronchopleural fistulas, and treat lymphedema.

Omfiloctocog alfa

Omfiloctocog alfa (SCT800, Anjiayin) is a B-domain-deleted recombinant factor VIII by Sinocelltech, the first domestic rFVIII approved in China (2021) for hemophilia A prophylaxis; also marketed as Hemofe in Indonesia.

Omidubicel

Omidubicel, sold as Omisirge, is a nicotinamide-expanded cord blood cell therapy approved by the FDA in 2023 to speed neutrophil recovery and reduce infections after transplantation.

Omiganan

Omiganan (MBI 226, CLS001) is a synthetic 12-amino-acid cationic antimicrobial peptide, an indolicidin analog from bovine neutrophils, that kills bacteria and fungi by disrupting cytoplasmic membranes and has been tested topically for catheter infections, rosacea, and dermatoses.

Oct 20, 2026

OMLTPT trial

OMLTPT (NCT02555501) was a Brazilian phase 3 split-mouth randomized trial comparing photodynamic therapy plus low-level laser against laser alone for chemotherapy-induced oral mucositis in patients aged 3 to 18, favoring the combined treatment.

Omodysplasia

Omodysplasia is a rare skeletal dysplasia with severe limb shortening and facial dysmorphism. Recessive form: GPC6 mutations (13q31), severe short stature; dominant form: FZD2 mutations, upper limbs only, normal height. Fewer than 40 cases reported.

Omohyoid muscle

The omohyoid muscle (musculus omohyoideus) is a paired infrahyoid muscle of the anterior neck running from the upper scapula to the hyoid bone, which it depresses after swallowing.

OMOP common data model

The OMOP common data model is an open data standard that harmonizes observational health data such as electronic health records and claims, maintained by the OHDSI collaboration for network research.

Omphalitis of newborn

Omphalitis of newborn (omphalitis neonatorum, ICD-10 P38) is a bacterial infection of the umbilical cord stump in the first 28 days of life, polymicrobial, with sepsis as the main complication; incidence 0.2–0.7% in industrialized countries, up to 22% where home birth is common.

Omphalocele

Omphalocele (exomphalos) is a congenital abdominal wall defect in which intestines, liver, or other organs herniate through the umbilicus inside a membranous sac, distinguishing it from gastroschisis; treated surgically, often staged, with about 1 in 3,704 US births affected.

Omphalocele-diaphragmatic hernia-cardiovascular anomalies-radial ray defect syndrome

Omphalocele-diaphragmatic hernia-cardiovascular anomalies-radial ray defect syndrome, or Gershoni-Baruch syndrome (OMIM 609545), an extremely rare autosomal recessive multiple congenital anomaly disorder, mostly fatal neonatally, with fewer than ten reported patients.

Omphalomesenteric cyst

Omphalomesenteric cyst (vitelline duct cyst, enterocystoma): rare congenital abdominal wall malformation from a persisting omphalomesenteric duct segment, GI-differentiated epithelium, ICD-10 Q43.0, presenting in childhood.

Oct 20, 2026

Omsk hemorrhagic fever

Omsk hemorrhagic fever (OHF), caused by Omsk hemorrhagic fever virus (OHFV), a tick-borne flavivirus, is a rare biphasic hemorrhagic disease of western Siberia (Omsk, Novosibirsk, Kurgan, Tyumen), spread by ticks and muskrats, with 0.5–3% fatality and no specific treatment or vaccine.

On (company)

On (On Holding AG, NYSE: ONON) is a Swiss premium sportswear company founded in 2010, known for CloudTec running shoes and LightSpray; 2025 net sales reached CHF 3,014.0 million, up 30%.

Onartuzumab

Onartuzumab (MetMAb, OA-5D5) is Genentech's humanized monovalent anti-MET monoclonal antibody blocking HGF binding; phase III METLung and later meta-analyses showed no survival benefit in NSCLC, gastric, or colorectal cancer, and it was never approved.

Onasemnogene abeparvovec

Onasemnogene abeparvovec (Zolgensma, Itvisma) is an AAV9 gene therapy delivering the SMN1 gene for spinal muscular atrophy; FDA-approved 2019 intravenously under age 2 and 2025 intrathecally for age 2 and older.

Onchocerciasis

Onchocerciasis, or river blindness, is a parasitic eye and skin disease caused by Onchocerca volvulus, spread by Simulium blackflies near fast rivers; treated with ivermectin MDA, with Niger the first African country verified free in 2025.

Oct 22, 2026

Onchocerciasis Control Programme

The Onchocerciasis Control Programme (OCP) was a WHO-led program that fought river blindness in West Africa from 1974 to 2002, chiefly by aerial spraying of blackfly breeding sites.

Onco-anesthesia

Onco-anesthesia, also written oncoanaesthesia or oncologic anesthesia, is specialized anesthesia care for cancer patients, formalized as a MeSH term in 2025 after roughly a decade of growth.